50 reports

  • PRODUCT PROFILE - ENCORAFENIB +BINIMETINIB

NY-ESO-## IS A CANCER ANTIGEN EXPRESSED IN A VARIETY OF CANCERS, INCLUDING COLORECTAL, RENAL AND ESOPHAGEAL.

  • Colorectal Cancer
  • Product Initiative
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

Colorectal cancer

4385 5000 3900
  • Colorectal cancer Disease Coverage | Pipeline: Colorectal Cancer
  • CAMPTOSAR FOR COLORECTAL CANCER - SWOT ANALYSIS

TS-## FORECAST, 2015-## FIGURE ##: TS-## SALES FOR COLORECTAL CANCER IN JAPAN ($M), 2015-## TABLE ##: TS-## SALES FOR COLORECTAL CANCER IN JAPAN ($M), 2015-## The table below shows Datamonitor Healthcare' s forecast of the total number

  • Colorectal Cancer
  • European Union
  • North America
  • United States
  • Product Initiative
  • Products under Investigation by Universities/Institutes, H1 2019
  • Number of Products under Development by Indication, H1 2019

One of these trials was Jun ##, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer completed at Rutgers Cancer Institute in patients with pancreatic cancer.

  • Colorectal Cancer
  • Medical Biotechnology
  • Monoclonal Antibody
  • Product Initiative
  • Etubics Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020 (CONTD..1), H1 2020
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2020

Colorectal cancer (CRC) is the second leading cause of cancer mortality in the U. S.

  • Colorectal Cancer
  • Leukemia
  • United States
  • Product Initiative
  • Onconova Therapeutics, Inc.
  • COLORECTAL CANCER
  • COLORECTAL CANCER

COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER METASTATIC COLORECTAL CANCER PRECLINICAL COLORECTAL CANCER COLORECTAL CANCER COLORECTAL CANCER COLORECTAL

  • Colorectal Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative
  • Merck & Co., Inc.
  • Metastatic Colorectal Cancer - Dormant Projects
  • Metastatic Colorectal Cancer - Discontinued Products

Metastatic Colorectal Cancer - Dormant Projects METASTATIC COLORECTAL CANCER - DORMANT PROJECTS (CONTD.. ##), H## 2016 METASTATIC COLORECTAL CANCER - DORMANT PROJECTS (CONTD.. ##), H## 2016 METASTATIC COLORECTAL CANCER - DORM

  • Colorectal Cancer
  • Research And Development
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Metastatic Colorectal Cancer
  • Products under Investigation by Universities/Institutes, H2 2018

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • Product Initiative
  • Etubics Corporation
  • Pipeline by Jazz Pharmaceuticals Plc, H1 2020
  • Number of Products under Development by Indications, H1 2020

A Phase ##/ ## clinical trial of defactinib in combination with CH## (VS-##) in patients with KRAS mutant advanced solid tumors, including low grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) is

  • Colorectal Cancer
  • Oncology
  • Targeted Therapy
  • Product Initiative
  • Bayer AG
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2020
  • AAT-008

The trial will include patients suffering with advanced or progressive microsatellite stable (MSS) colorectal cancer (CRC), and with advanced or metastatic PD-##/ L## refractory non-small cell lung cancer (NSCLC) adenocarcinoma.

  • Colorectal Cancer
  • China
  • World
  • Product Initiative
  • Eisai Co., Ltd.
  • free survival (PFS), overall survival (OS) and duration of response.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2019

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Product Initiative
  • Aug 26, 2019: FDA approves HLB's phase 1b/2 clinical trial for colorectal cancer
  • Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Dormant Products

National Institutes of Health. treatment as the neoadjuvant therapy in advanced colorectal cancer.

  • Colorectal Cancer
  • Targeted Therapy
  • Therapy
  • Product Initiative
  • Athenex, Inc.
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2019

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • Product Initiative
  • Etubics Corporation

Colorectal Cancer Pipeline Highlights – 2017 ##.

  • Cancer
  • Colorectal Cancer
  • United States
  • Product Initiative
  • PIPELINE BY ENTRECHEM SL, H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2019

The prognosis of colorectal cancer is poor due to the limited therapeutic options and the lack of specific targeted agents.

  • Colorectal Cancer
  • Therapy
  • World
  • Product Initiative
  • IMMD
  • SMALL MOLECULES TO AGONIZE DR4 AND DR5 FOR COLORECTAL CANCER - DRUG PROFILE
  • PIPELINE BY ABBVIE INC, H1 2018

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Colorectal Cancer
  • Hospital
  • Medical Biotechnology
  • Product Initiative
  • GlaxoSmithKline plc
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019 (CONTD..1), H2 2019

One group will receive nivolumab and the standard chemotherapy given for colorectal cancer that has spread to the liver in addition to surgery.

  • Colorectal Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2020 (CONTD..1), H1 2020
  • PIPELINE BY EFFECTOR THERAPEUTICS INC, H1 2020

The drug candidate is in Phase II stage of development for microsatellite stable relapsed or refractory colorectal cancer.

  • Cancer
  • Colorectal Cancer
  • Therapy
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..1), H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019

The drug candidate is in Phase II stage of development for microsatellite stable relapsed or refractory colorectal cancer.

  • Colorectal Cancer
  • Therapy
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2019 (CONTD..1), H2 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2019

The drug candidate is in Phase II stage of development for microsatellite stable relapsed or refractory colorectal cancer.

  • Cancer
  • Colorectal Cancer
  • Lymphoma
  • Therapy
  • Product Initiative
  • PIPELINE BY ENTRECHEM SL, H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018

The prognosis of colorectal cancer is poor due to the limited therapeutic options and the lack of specific targeted agents.

  • Colorectal Cancer
  • Targeted Therapy
  • World
  • Product Initiative
  • IMMD
  • IO Marketed Product Lifecycle Development in Colorectal Cancer
  • OF CONTENTS (2/4)

Colorectal cancer ##.

  • Clinical Trial
  • Colorectal Cancer
  • Epidemiology
  • Therapy
  • Product Initiative
  • Clinical Trial profile. 38 Trial Title
  • Clinical Trial profile. 44 Trial Title

Falk Pharma GmbH ## Jul 2012 ## Jun 2015 ## ## ## ## Prostaglandin G/ H Synthase (Cyclooxygenase or COX or PTGS or EC ##. ##. ##. ##) Inhibitor Prostaglandin G/ H Synthase (Cyclooxygenase or COX or PTGS or EC ##. ##. ##. ##) Pilot Trial on Efficacy of Single Dose Perioperative Intraven

  • Colorectal Cancer
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • EMI-137 - Product Description

Cancer ## Lung Disease ## Lung Fibrosis ## Nodules ## Oral Squamous Cell Carcinoma ## Pancreatic Cancer ## Prostate Cancer ## Thyroid Cancer ## Colorectal Cancer ## Gastric Cancer

  • Colorectal Cancer
  • Diagnostic Imaging
  • Nuclear Imaging Equipment
  • United Kingdom
  • Product Initiative
  • Metastatic Colorectal Cancer - Discontinued Products
  • Metastatic Colorectal Cancer - Dormant Projects

Qualified subjects, who have KRAS WT colorectal cancer will be randomized in a ##:## ratio to either: Arm ## which contains Imprime PGG and cetuximab or Arm ## containing cetuximab.

  • Colorectal Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Product Initiative
  • PIPELINE BY ENTRECHEM SL, H1 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2018

The prognosis of colorectal cancer is poor due to the limited therapeutic options and the lack of specific targeted agents.

  • Brain Cancer
  • Colorectal Cancer
  • World
  • Product Initiative
  • IMMD
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018

" We saw promising indications of efficacy in metastatic colorectal cancer patients in our phase ##/ ##a clinical study of apatinib, " noted Dr.

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • Therapy
  • Product Initiative

Interleukin ## Alpha (IL ## Alpha or Hematopoietin ## or IL##A) - Pipeline Review, H## 2016 GMDHC##TDB / Pub December 2016 advanced colorectal cancer (CRC).

  • Colorectal Cancer
  • Pharmaceutical
  • Europe
  • Product Initiative
  • XBiotech Inc.

Cancer ## Colorectal Cancer ## Gastric Cancer ## Breast Cancer ## Cancer ## Ovarian Cancer ## Pancreatic Cancer ## Indication No of Products Guardant Health Inc - Pipeline Analysis Overview

  • Colorectal Cancer
  • Genetic Testing
  • Hospital
  • Product Initiative
  • Guardant Health, Inc.
  • SMALL MOLECULES TO AGONIZE DR4 AND DR5 FOR COLORECTAL CANCER - DRUG PROFILE
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..1), H2 2017

THE PHASE ## TRIAL IN COLORECTAL CANCER IS ONGOING, WITH A PRESENTATION OF THE RESULTS ANTICIPATED ON NOVEMBER ## AT THE 2005 EUROPEAN CANCER CONFERENCE (ECCO).

  • Colorectal Cancer
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Product Initiative
  • Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products

It was also under development for the treatment of advanced colorectal cancer, non-small cell lung cancer, relapsed or refractory Hodgkin' s lymphoma, advanced hepatocellular carcinoma and other solid tumors.

  • Cancer
  • Colorectal Cancer
  • Pharmaceutical
  • Therapy
  • Product Initiative